Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2024 / Dec / Deciphering Alzheimer’s Proteins
Genetics and epigenetics

Deciphering Alzheimer’s Proteins

Genetic data and protein modeling uncovers biomarkers for Alzheimer’s disease

By Jessica Allerton 12/13/2024 News 1 min read

Share

A recent study in Cell Genomics has identified seven plasma proteins associated with Alzheimer’s disease (AD), providing new insights into the disease and potential paths for diagnostics. Using a novel method called MR-SPI, researchers combined genetic data and protein structure predictions to uncover biomarkers and explore how genetic mutations alter protein structures.

Credit: Adobe Stock

The study analyzed data from over 54,000 individuals in the UK Biobank and more than 455,000 participants in a genome-wide association study. Seven proteins – TREM2, PILRB, PILRA, EPHA1, CD33, RET, and CD55 – were linked to Alzheimer’s risk. Some, like TREM2, appeared to protect against the disease, while others, like CD33, increased risk. Advanced modeling with AlphaFold3 revealed how mutations in these proteins may disrupt their structure and function. For instance, a mutation in CD33 changes its amino acid composition, potentially affecting how brain immune cells clear amyloid plaques.

MR-SPI, a new statistical approach, allowed the researchers to pinpoint proteins with strong links to Alzheimer’s by selecting reliable genetic markers, even with limited data. This method outperformed existing techniques in accuracy and reliability. These biomarkers could aid in the early detection of Alzheimer’s disease, particularly in individuals with genetic predispositions. Several identified proteins, such as TREM2 and CD33, have known roles in neuroinflammation and amyloid processing, suggesting their utility in developing targeted therapies.

While the study noted some limitations, such as potential biases in pQTL selection and reliance on publicly available GWAS data, it represents a major step forward in understanding the molecular drivers of Alzheimer’s disease. By pinpointing proteins such as TREM2 and CD33 as potential therapeutic targets, this study not only enhances understanding of Alzheimer’s disease pathophysiology, but also opens doors for innovative diagnostic tools, the authors say.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Jessica Allerton

Deputy Editor, The Pathologist

More Articles by Jessica Allerton

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Breathing New Life into Diagnostics
Genetics and epigenetics
Breathing New Life into Diagnostics

January 22, 2024

6 min read

Jonathan Edgeworth on how metagenomics could transform testing for respiratory infections

Molecular Spectacular
Genetics and epigenetics
Molecular Spectacular

January 8, 2024

1 min read

A look at last year’s most interesting molecular pathology stories

Redefining Diagnostic Reference Standards
Genetics and epigenetics
Redefining Diagnostic Reference Standards

January 3, 2022

1 min read

Find out what Horizon Discovery’s diagnostic reference standards can do for your workflow

Defining the Next Generation of NGS
Genetics and epigenetics
Defining the Next Generation of NGS

December 31, 2021

1 min read

Overcoming challenges of the typical NGS workflow with the Ion Torrent™ Genexus™ System

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.